CG Oncology Up 14% as Nasdaq Fell 2.5%: A Phase 3 Filing
With the S&P 500 down 1.92%, CG Oncology rose on a Phase 3 trial filing, Telus on a reported Quebecor takeover offer, and Molina on Medicaid policy news with no company filing.

Seoul — U.S. stocks fell on Nov. 16, with the S&P 500 down 1.92%, the Nasdaq Composite down 2.49% and the Russell 2000 down 1.70%. Three stocks still rose more than 10%: CG Oncology (CGON), TELUS Corporation (TU) and Molina Healthcare, Inc. (MOH). Only CG Oncology's move is confirmed by a company filing. Telus rose on takeover-offer reports, and Molina on policy news. (Screen: regular-session gains of 10% or more, 3 stocks; 1 confirmed by filing.)

A record of confirmed facts, not stock recommendations.
At a glance
| Stock | Why it rose | Nature | Evidence | Heat | What to check next |
|---|---|---|---|---|---|
| CG Oncology (CGON) +13.95% | Phase 3 PIVOT-006 results | Substantive, one-off | Filing confirmed (positive) | 1/4 | Detailed data in Exhibit 99.1 |
| TELUS (TU) +12.19% | Quebecor takeover offer reported | Expectation | Reports only | 1/4 | Board and regulator response |
| Molina (MOH) +11.27% | Medicaid work-requirement delay reported | Expectation | Reports only | 0/4 | Whether volume holds next day |
CG Oncology rose 14% on Phase 3 bladder cancer results
CG Oncology (CGON) rose 13.95% to $84.78 after announcing results from its Phase 3 PIVOT-006 trial. In an 8-K (current report) filed with the U.S. Securities and Exchange Commission, under Items 7.01, 8.01 and 9.01, the company said it issued a press release on Nov. 16 titled "PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)." Benzinga reported the trial met its primary endpoint with compelling safety and tolerability results.
The stock is up 20.9% over two days and 13.4% over five, and rose 17.27% on Nov. 6 as well. It is 35.9% higher than on Oct. 13. Market value is about $7.57 billion and dollar volume was about $838 million. The 8-K confirms the announcement and the press release title; the specific figures are in Exhibit 99.1.
On the heat check, 1 of 4 overheating signals is lit, labeled "caution." Volume was 8.2 times the 20-day average, RSI was 73.9 and the price was 25.7% above its 20-day average. It closed at the top of its 52-week range, 26.8% above its 200-day average. It passed 1 of 6 fundamentals checks, and revenue fell 3.7%. The trial result is documented substance, but it is a single announcement.
What to watch is the actual RFS data and safety tables in Exhibit 99.1, plus any regulatory submission plan the company gives. Whether volume near $800 million holds the next day also matters.
TELUS rose 12% on a reported Quebecor takeover offer
TELUS (TU) rose 12.19% to $9.57 on reports that Quebecor made a roughly C$31 billion offer for the company. CBC ran the headline "Quebecor makes $31B offer to acquire Telus," and Bloomberg reported that CEO Dodig called the bid undervalued. BNN Bloomberg's headline said Telus sees "serious concerns" with it.
The only SEC filing that day was a 6-K (foreign issuer report) with no item detail, so it does not confirm the offer. The evidence is press reports. A Financial Post headline said competition questions cloud the offer. The stock is up 12.3% over two days and 7.3% over five.
Heat is 1 of 4 signals (volume 7.2 times average, RSI 65.5). The stock sits at 28% of its 52-week range, 33.1% below its high and 13.6% below its 200-day average. It passed 1 of 6 fundamentals checks.
Watch how the Telus board formally responds and how Canadian competition authorities react. Trading in the following days will show how much of the offer the price already reflects.
Molina rose 11% with Medicaid delay news and no company filing
Molina Healthcare (MOH) rose 11.27% to $233.09 on expectations that Medicaid work requirements would be delayed. Yahoo's headline read "Medicaid Work Requirement Delay Pushes Molina, Centene Stocks Higher." The company filed no major-event report.
Its SEC filings over the past week are insider-trade reports (Form 4) and proposed-sale notices (Form 144): one of each on Nov. 16, and five Form 4s and one Form 144 on Nov. 13. Their size and direction cannot be seen from the filing listing. The stock rose 8.93% on Nov. 4, and is up 11.1% over two days and 14.6% over five.
Heat is 0 of 4 (volume 1.8 times average). It sits at 92% of its 52-week range, 4.0% below its high and 25.3% above its 200-day average. It passed 2 of 6 fundamentals checks, and revenue fell 3.5%.
Watch whether the delay becomes actual policy, and whether upcoming Form 4 and 144 filings include insider selling.
Previously covered stocks since then
| Stock | Verdict then | Close on article date | Close Nov. 16 | Change |
|---|---|---|---|---|
| Modine Manufacturing (MOD) | Reports | 135.66 | 130.55 | -3.8% |
| Liftoff Mobile (LFTO) | Earnings | 24.44 | 24.46 | +0.1% |
| Stantec (STN) | Earnings | 85.69 | 84.08 | -1.9% |
| Mobility Global (MBGL) | Filing | 23.13 | 24.04 | +3.9% |
| Chagee (CHA) | Reports | 13.51 | 13.93 | +3.1% |
| Belite Bio (BLTE) | Reports | 169.96 | 162.56 | -4.4% |
| CoreWeave, Inc. (CRWV) | Earnings | 60.77 | 49.88 | -17.9% |
| Azenta, Inc. (AZTA) | Earnings | 48.90 | 47.22 | -3.4% |
CoreWeave, which rose on earnings, fell the most at 17.9%. Stocks that rose on reports split, with Modine and Belite lower and Chagee higher.
FAQ
Why did CG Oncology, Inc. stock go up?
Phase 3 PIVOT-006 results. Evidence: Filing confirmed (positive). What to check next: 1/4.
Why did TELUS Corporation stock go up?
Quebecor takeover offer reported. Evidence: Reports only. What to check next: 1/4.
Why did Molina Healthcare, Inc. stock go up?
Medicaid work-requirement delay reported. Evidence: Reports only. What to check next: 0/4.